Table 4.
Correlation between CD109 expression and clinicopathological characteristics in ovarian epithelial carcinomas (n = 120)
| Parameter | Negative | Positive | p-valuea |
|---|---|---|---|
| Histologic type | .000 | ||
| Serous | 13 (22.0) | 46 (78.0) | |
| Mucinous | 19 (86.4) | 3 (13.6) | |
| Endometrioid | 3 (33.3) | 6 (66.7) | |
| Clear cell | 22 (81.5) | 5 (18.5) | |
| Undifferentiated | 0 (0) | 3 (100) | |
| Histologic grade | .012 | ||
| Well differentiated | 19 (67.9) | 9 (32.1) | |
| Moderate differentiated | 29 (47.5) | 32 (52.5) | |
| Poorly differentiated | 9 (29.0) | 22 (71.0) | |
| Nuclear grade | .788 | ||
| I | 3 (50.0) | 3 (50.0) | |
| II | 29 (44.6) | 36 (55.4) | |
| III | 25 (51.0) | 24 (49.0) | |
| FIGO stage | .000 | ||
| I | 39 (76.5) | 12 (23.5) | |
| II, III and IV | 18 (26.1) | 51 (73.9) | |
| Mitoses (per 10HPFs) | .000 | ||
| 1–9 | 32 (71.1) | 13 (28.9) | |
| ≥ 10 | 25 (33.3) | 50 (66.7) |
Negative, less than 10% positive staining of tumor cells; Positive, more than 10% positive staining of tumor cells.
FIGO, Federation of Gynecology and Obstetrics; HPF, high power field.
a
Pearson’s chi-squared test.